Search results
Aug 14, 2024 · In 2015 Dr. Melton founded Semma Therapeutics to develop these stem cells into curative therapies for T1D. In 2017, the JDRF T1D Fund made a significant investment in Semma. In 2019, Vertex acquired Semma for almost $1 billion USD.
Sep 3, 2019 · Implantation of the islet cell-filled device has the potential to replace the missing beta cells in a diabetic patient without requiring patient immunosuppression. Semma is working to bring this new therapeutic option to the clinic and improve the lives of patients with diabetes.
- Understanding The Background to The Deal
- Pharma Executives Respond to The Acquisition
- Semma Share Price and Company Overview
- Vertex Share Price and Company Overview
Vertex announced its intentions to move into new disease areas, embrace new technology and pursue more deals in a July meeting with investors, according to BioPharmaDive. The Semma acquisition builds upon Vertex’s agreement to buy gene-editing specialist Exonics Therapeutics in June. Semma recently completed two proof-of-concept animal studies of i...
Vertex chairman, president and outgoing CEO Jeffrey Leiden commented: “This acquisition aligns perfectly with our strategy of investing in scientific innovation to create transformative medicines for people with serious diseases in specialty markets. “We are excited to work with the talented scientists at Semma to build on their significant progres...
Privately held company Semma is based in Boston and was founded by Professor Douglas Melton, who will remain as the chair of Semma’s scientific advisory board. The company leverages Melton’s laboratory work to produce functional insulin-producing beta cells for type 1 diabetes patients.
With headquarters in Boston and London, Vertex is an innovation-focused company most well-known for its combination cystic fibrosis drugs, including Orkambi and Symkevi. However, the company also has drugs in the pipeline for pain and genetic disorder Alpha-1 Antitrypsin Deficiency. Listed on the New York Stock Exchange, Vertex’s share price droppe...
Sep 3, 2019 · The cystic fibrosis specialist is snapping up Semma Therapeutics and its stem cell-based diabetes treatments for $950 million in an all-cash deal slated to close in the fourth quarter. Douglas...
Sep 3, 2019 · -Semma’s unique investigational approach combines robust production process of pancreatic islet cells with proprietary delivery system to restore insulin secretion in type 1 diabetes...
Mar 24, 2022 · Vertex Pharmaceuticals will acquire all outstanding shares of biotechnology firm Semma Therapeutics for a cash sum of $950m. Semma has developed a technique to generate vast quantities of functional, insulin-producing human pancreatic beta cells from stem cells for the treatment of patients with type 1 diabetes.
People also ask
Who owns Semma Therapeutics?
Will Vertex Pharmaceuticals buy Semma Therapeutics?
Why should you join Semma Therapeutics?
What are the terms of the Semma acquisition?
Mar 24, 2015 · CAMBRIDGE, Mass. – Semma Therapeutics, a company developing a cell therapy for Type 1 diabetes, announced today that it has closed a $44 million Series A consisting of equity financing and...
